A Prospective, Single-Arm, Two-Stage, Open-Label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Lexibulin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Mar 2011 Planned end date changed from 1 Dec 2009 to 1 Feb 2011 as reported by ClinicalTrials.gov .
- 07 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov .
- 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.